We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
AbCellera Biologics
ABCL
$2.12B
| $8M | ﹤0.01% |
808,656
+124,345
| +18% | +$1.36M |
|
1602
Alignment Healthcare
ALHC
$2.98B
| $7.98M | ﹤0.01% |
674,077
+82,242
| +14% | +$1.2M |
|
1603
Cogent Communications
CCOI
$508M
| $7.98M | ﹤0.01% |
153,027
-3,119
| -2% | -$180K |
|
1604
Enact Holdings
ACT
$6.73B
| $7.96M | ﹤0.01% |
359,223
+115,789
| +48% | +$2.78M |
|
1605
Hawaiian Electric Industries
HE
$2.14B
| $7.95M | ﹤0.01% |
229,229
-8,008
| -3% | -$322K |
|
1606
Credit Acceptance
CACC
$6.08B
| $7.94M | ﹤0.01% |
18,128
-1,820
| -9% | -$960K |
|
1607
Rithm Capital
RITM
$5.69B
| $7.92M | ﹤0.01% |
1,081,774
-47,961
| -4% | -$457K |
|
1608
Banc of California
BANC
$2.97B
| $7.91M | ﹤0.01% |
495,266
-417,822
| -46% | -$7.28M |
|
|
CTIC
1609
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $7.88M | ﹤0.01% |
1,353,509
-396,684
| -23% | -$2.47M |
|
1610
Laureate Education
LAUR
$5.28B
| $7.87M | ﹤0.01% |
745,968
-446,627
| -37% | -$5.06M |
|
|
IBTX
1611
DELISTED
Independent Bank Group, Inc.
IBTX
| $7.82M | ﹤0.01% |
127,418
-9,955
| -7% | -$687K |
|
1612
Timken Company
TKR
$9.03B
| $7.82M | ﹤0.01% |
132,414
-3,088
| -2% | -$192K |
|
1613
NETSCOUT
NTCT
$2.79B
| $7.8M | ﹤0.01% |
249,154
-9,555
| -4% | -$313K |
|
1614
Nabors Industries
NBR
$1.21B
| $7.8M | ﹤0.01% |
76,869
+12,111
| +19% | +$1.48M |
|
1615
Trustmark
TRMK
$2.75B
| $7.79M | ﹤0.01% |
254,450
-4,721
| -2% | -$150K |
|
1616
Vertiv
VRT
$105B
| $7.78M | ﹤0.01% |
800,215
-43,250
| -5% | -$486K |
|
|
UMPQ
1617
DELISTED
Umpqua Holdings Corp
UMPQ
| $7.77M | ﹤0.01% |
454,604
-10,228
| -2% | -$182K |
|
|
VGR
1618
DELISTED
Vector Group Ltd.
VGR
| $7.75M | ﹤0.01% |
880,098
-81,874
| -9% | -$830K |
|
|
FLG
1619
Flagstar Bank National Association
FLG
$5.82B
| $7.72M | ﹤0.01% |
301,864
-10,119
| -3% | -$297K |
|
|
KYNB
1620
Kyntra Bio
KYNB
$29.4M
| $7.72M | ﹤0.01% |
23,729
+13,136
| +124% | +$4.23M |
|
1621
Brighthouse Financial
BHF
$3.5B
| $7.71M | ﹤0.01% |
177,477
-22,219
| -11% | -$1.01M |
|
1622
Winnebago Industries
WGO
$909M
| $7.71M | ﹤0.01% |
144,823
-51,148
| -26% | -$2.97M |
|
1623
Warrior Met Coal
HCC
$4.86B
| $7.71M | ﹤0.01% |
270,932
-26,178
| -9% | -$805K |
|
|
ECHO
1624
EchoStar
ECHO
$26.2B
| $7.7M | ﹤0.01% |
467,740
-2,114
| -0.4% | -$39.5K |
|
1625
Kontoor Brands
KTB
$4.26B
| $7.68M | ﹤0.01% |
228,410
-25,242
| -10% | -$936K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.